ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

E-3810

Also written as “E3810”, “Lucitanib” and “AL3810”.

Its studies are mostly in Thymoma · Genital Neoplasms, Female · Breast Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.

Drug pageE-3810: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 12, 200511 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eisaiits history only40 open or runningphase 3since Sep 12, 2005Sep 12, 2005none ahead
Haihe Biopharma40 open or runningphase 3since Jan 16, 2020Dec 16, 2016none ahead
Clovis Oncologyits history only30 open or runningphase 2since Apr 7, 2014Apr 7, 2014none ahead

Also a collaborator on its studies: Bristol-Myers Squibb.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Haihe Biopharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2016First study: phase 1 study in Advanced Solid TumorsFirst studyNCT03117101 · 17 enrolled · China
  2. Jul 20, 2017Phase 1 study in Colorectal NeoplasmsNCT03260179 · 60 enrolled · China
  3. Jan 16, 2020Phase 3 study in Small Cell Lung CarcinomaNCT04254471 · 313 enrolled · China
  4. Sep 11, 2026Phase 2 study in ThymomaNCT07824505 · 74 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Haihe Biopharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07824505Thymoma · China2CompletedSep 6, 202174
NCT04254471Small Cell Lung Carcinoma · China3UNKNOWNMay 22, 2022313
NCT03260179Colorectal Neoplasms · China1UNKNOWNJan 31, 201960
NCT03117101Advanced Solid Tumors · China1CompletedSep 201617

How it is read

Names in the registry

  • “E3810”, 8 entries
  • “Lucitanib”, 6 entries
  • “AL3810”, 4 entries
  • “lucitanib 15 mg QD”, 1 entry
  • “lucitanib 10 mg QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.